| $385M | ||
| $350M | ||
| $215M | ||
| $107M | ||
| $100M | ||
| $91M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter. Beyond this, Genenta Science is exploring Temferon's potential application in various other solid tumor types, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Established in 2014, the company maintains its headquarters in Milan, Italy.
Over the last 12 months, insiders at Genenta Science S.p.A. have bought $0 and sold $0 worth of Genenta Science S.p.A. stock.
On average, over the past 5 years, insiders at Genenta Science S.p.A. have bought $0 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 25,000 shares for transaction amount of $18,750 was made by Sanders Walter Lloyd (VP, Sales & Marketing) on 2006‑11‑15.
| 2006-11-15 | Sanders Walter Lloyd | VP, Sales & Marketing | 25,000 0.0197% | $0.75 | $18,750 | |||
| 2006-06-23 | Sanders Walter Lloyd | VP, Sales & Marketing | 56 <0.0001% | $1.63 | $91 | |||
| 2006-06-15 | Sanders Walter Lloyd | VP, Sales & Marketing | 577 0.0009% | $1.51 | $874 | |||
| 2006-05-12 | Driscoll Martin J | director | 15,000 0.023% | $1.46 | $21,900 | |||
| 2004-05-05 | Sale | ROSENWALD LINDSAY A MD | 10 percent owner | 940,000 4.8924% | $4.95 | $4.65M | ||
| 2004-05-04 | Sale | ROSENWALD LINDSAY A MD | 10 percent owner | 6.31M 32.6423% | $4.92 | $31.05M | ||
| 2004-05-03 | Sale | ROSENWALD LINDSAY A MD | 10 percent owner | 2.75M 14.6019% | $5.05 | $13.89M | ||
| 2004-03-23 | ROSENWALD LINDSAY A MD | 10 percent owner | 5,000 0.0495% | $9.42 | $47,100 | |||
| 2004-03-16 | ROSENWALD LINDSAY A MD | 10 percent owner | 5,000 0.0541% | $10.29 | $51,450 | |||
| 2003-10-20 | ROSENWALD LINDSAY A MD | 10 percent owner | 5,000 0.0529% | $10.07 | $50,350 | |||
| 2003-09-10 | ROSENWALD LINDSAY A MD | 10 percent owner | 5,000 0.0824% | $15.68 | $78,400 |
| Increased Positions | 11 | +220% | 2M | +391.69% |
| Decreased Positions | <1 | -20% | 332 | -0.06% |
| New Positions | 9 | New | 1M | New |
| Sold Out Positions | 0 | Sold Out | 0 | Sold Out |
| Total Postitions | 15 | +200% | 3M | +391.63% |
| Allianz Se | $330.00 | 1.02% | 234,050 | 0 | 0% | 2025-09-30 |
| Alti Global, Inc. | $282.00 | 0.87% | 200,288 | 0 | 0% | 2025-09-30 |
| Algebris (Uk) Ltd | $141.00 | 0.44% | 100,000 | 0 | 0% | 2025-09-30 |
| Citadel Advisors Llc | $18.00 | 0.05% | 12,486 | +12,486 | New | 2025-09-30 |
| National Bank Of Canada /Fi/ | $4.00 | 0.01% | 3,000 | +3,000 | New | 2025-09-30 |
| Morgan Stanley | $3.00 | 0.01% | 2,200 | +200 | +10% | 2025-09-30 |
| Eversource Wealth Advisors, Llc | $0 | 0% | 0 | -982 | Sold Out | 2025-09-30 |